What could account for this small percentage of tumors found to be responsive to glucocorticoid treatment is the observation that the glucocorticoid receptor (GR) is lost in up to 85% of all prostate cancers during progression [39]. The gene discussed is NR3C1; the disease is prostate carcinoma.